To examine inhibition of RET in the context of both treatment naïve and chemotherapy-refractory tumors, we turned to 2 KIF5B-RET NSCLC PDX models (N=10 replicates/condition). The gene discussed is RET; the disease is non-small cell lung carcinoma.